FDC
410.65
-1.75(-0.42%)
Market Cap₹6,685.80 Cr
PE Ratio29.74
IndustryHealthcare
Company Performance:
1D-0.42%
1M+0.31%
6M-10.59%
1Y-16.00%
5Y+25.18%
View Company Insightsright
More news about FDC
05Sept 25
FDC Limited Reports Strong Q1 Results, Approves Share Buyback and Director Reappointments
FDC Limited reported robust Q1 FY2024 results with revenue of Rs. 53,003.98 lakhs and net profit of Rs. 10,855.13 lakhs. The company approved a share buyback of 31 lakh equity shares at Rs. 500 per share, totaling Rs. 155 crores. The board reappointed three key directors for five-year terms. FDC also approved acquisition of an additional 7% stake in its subsidiary, Fair Deal Corporation Pharmaceutical SA, making it a wholly-owned entity.
07Aug 25
FDC Limited Reports Robust Q1 Performance with 33% Profit Growth
FDC Limited announced impressive Q1 financial results, with consolidated revenue reaching Rs. 648.41 crore and net profit at Rs. 121.35 crore. The company saw a 2.9% increase in standalone revenue and a 33% rise in consolidated net profit compared to the same quarter last year. The Board also approved the reappointment of Mr. Ashok A. Chandavarkar as Executive Director for a five-year term starting March 1, 2026, subject to shareholder approval.
07Aug 25
FDC Reports Steady Q1 Performance with Marginal Revenue Growth
FDC Limited's Q1 financial results show a steady performance. The company maintained a consolidated net profit of ₹120.00 crore, identical to last year's Q1. Revenue slightly increased to ₹650.00 crore from ₹640.00 crore, marking a 1.56% year-over-year growth. However, EBITDA decreased to ₹140.00 crore from ₹146.00 crore, with the EBITDA margin compressing to 21.54% from 22.81% year-over-year.
28May 25
FDC Reports Mixed Q4 Results: Revenue Up, Profit Down
FDC Limited's Q4 financial results show a 6.49% year-over-year revenue increase to ₹4.92 billion. However, profitability declined with EBITDA falling 4.12% to ₹539.80 crore and net profit decreasing 16.48% to ₹386.70 crore. The EBITDA margin compressed to 10.97% from 12.19% in the previous year.
30Apr 25
FDC Limited Approves Rs 140 Crore Expansion of Liquid Oral Facility at Sinnar Plant
FDC Limited has approved a Rs 140 crore expansion plan for its liquid oral facility at the Sinnar plant. The project will add 77,000 KL per annum to production capacity, to be completed in 18-24 months. Funded through internal accruals, this expansion aims to meet high capacity utilization (70-80%) and growing market demand. The investment is expected to strengthen FDC's manufacturing infrastructure and market position in the pharmaceutical sector.
FDC
410.65
-1.75
(-0.42%)
1 Year Returns:-16.00%
Industry Peers
Sun Pharmaceutical
1,755.90
(-0.79%)
Divis Laboratories
6,476.50
(-0.54%)
Torrent Pharmaceuticals
3,820.10
(+0.11%)
Cipla
1,500.70
(-0.81%)
Dr Reddys Laboratories
1,283.50
(+0.01%)
Lupin
2,113.50
(-0.60%)
Zydus Life Science
927.80
(+1.05%)
Mankind Pharma
2,229.60
(+1.98%)
Aurobindo Pharma
1,218.00
(-0.53%)
Alkem Laboratories
5,597.00
(-0.48%)